1 citations
,
June 2021 in “International journal of pharmaceutical compounding” This study found that compounded minoxidil solutions in a propylene glycol-free and alcohol-reduced foam remained stable for 180 days, meeting United States Pharmacopeia standards for strength, pH, and antimicrobial effectiveness.
December 2025 in “PubMed” In this study, researchers found that a propylene glycol-free and alcohol-reduced topical foam containing minoxidil and finasteride remained chemically, physically, and microbially stable for 180 days when stored properly at room temperature in light-resistant containers.
In this phase I study, CG2001, a topical foam combining minoxidil and finasteride, was found to be safe and well-tolerated in Chinese males with androgenetic alopecia, showing significantly reduced systemic finasteride exposure compared to oral administration, potentially reducing related side effects.
This study found that the novel alcohol-free topical foam CG2001, combining minoxidil and finasteride, was safe and well-tolerated in Chinese males with androgenetic alopecia, with significantly lower systemic exposure to finasteride compared to oral administration, potentially reducing sexual side effects.
1 citations
,
May 2021 in “Journal of Cosmetic Dermatology” This study found that a cosmetic foam reduced the telogen rate in men with androgenetic alopecia, suggesting a potential benefit against male pattern hair loss.